Compare ENOV & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENOV | COLL |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2008 | 2015 |
| Metric | ENOV | COLL |
|---|---|---|
| Price | $22.60 | $33.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $47.38 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 694.5K | 443.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $6.36 | $8.01 |
| Revenue Next Year | $5.31 | N/A |
| P/E Ratio | ★ N/A | $19.51 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $21.00 | $26.72 |
| 52 Week High | $36.82 | $50.79 |
| Indicator | ENOV | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 49.72 |
| Support Level | $21.52 | $31.18 |
| Resistance Level | $23.57 | $36.22 |
| Average True Range (ATR) | 1.25 | 1.31 |
| MACD | -0.26 | 0.22 |
| Stochastic Oscillator | 8.16 | 54.08 |
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.